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Protease inhibitorAcute diarrhea disease caused by bacterial infections is a major global health problem. Enterotoxigenic
Escherichia coli (ETEC) is one of the top causes of diarrhea-associated morbidity and mortality in young
children and travelers to low-income countries. There are currently no licensed vaccines for ETEC.
Induction of immunity at the site of entry of the bacteria is key to prevent infection. Current approaches
to ETEC vaccines include a less toxic mutant form of E. coli heat-labile toxin (double-mutant heat-labile
enterotoxin -dmLT-) with both antigenic and immunostimulatory properties. U-Omp19 is a protease
inhibitor from Brucella spp. with immunostimulatory properties that has been used as oral adjuvant. In
this work, we use U-Omp19 as adjuvant in an oral vaccine formulation against ETEC containing dmLT
in outbred and inbred mice. To evaluate antigen dose sparing by U-Omp19 three different immunization
protocols with three different doses of dmLT were evaluated. We demonstrated that U-Omp19 co-
delivery increases anti-LT IgA in feces using a mid-dose of dmLT following a prime-boost protocol (after
one or two boosts). Oral immunization with U-Omp19 induced protection against LT challenge when co-
formulated with dmLT in CD-1 and BALB/c mice. Indeed, there was a significant increase in anti-LT IgG
and IgA avidity after a single oral administration of dmLT plus U-Omp19 in comparison with dmLT deliv-
ered alone. Interestingly, sera from dmLT plus U-Omp19 vaccinated mice significantly neutralize LT effect
on intestine inflammation in vivo compared with sera from the group immunized with dmLT alone. These
results demonstrate the adjuvant capacity of U-Omp19 to increase dmLT immunogenicity by the oral
route and support its use in an oral subunit vaccine formulation against ETEC.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Acute enteric infections causing diarrhea and gastroenteritis
constitute a global public health problem with high mortality
and morbidity, particularly among children in low-income and
lower middle-income countries. Diarrhea ranked ninth among
causes of death for all ages, and fourth among infants, accounting
for an estimated 499,000 deaths in children under 5 years old
[1]. Enterotoxigenic Escherichia coli (ETEC) is among the top five
pathogens that cause diarrheal mortality in children and it also
causes significant burden across all ages [2].ETEC causes a secretory diarrhea that can range in presentation
from mild discomfort to a cholera-like illness. Transmission of
ETEC person-to-person occurs via ingestion of faecally-
contaminated food or water. In developed countries where sanita-
tion standards are usually higher, ETEC infection is rare. However,
it remains a leading cause of travelers’ diarrhea which occurs in
people visiting or returning from ETEC-endemic regions [3,4]. Epi-
demics of ETEC diarrhea have also occurred during natural disas-
ters, such as floods where the quality of drinking water and
sanitation were drastically affected [5].
This pathogen cause disease by colonization of the gut through
colonization factors (CFs), most of which are fimbriae that promote
the attachment of bacteria to host epithelial cells. They also pro-
duce and release enterotoxins (heat labile enterotoxin -LT- and/
or a non-immunogenic polypeptide heat-stable enterotoxin -ST-)
that disrupt fluid and electrolyte homeostasis in the small intes-
tine, leading to fluid hypersecretion and watery diarrhea [6].
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rehydration salts (ORS) and, where appropriate and available, the
use of antimicrobials. However, with the emergence of multi-
drug resistant strains of ETEC, the need for vaccines against this
pathogen is increased [7]. At present there is no vaccine specifically
licensed to prevent ETEC disease. The oral killed whole-cell cholera
vaccine, Dukoral, which is available for travelers in Canada and
Europe, contains the recombinant cholera toxin subunit B, which
is homologous with LT of ETEC and by extension provides partial
protection against this bacterium. Unfortunately, most ETEC
strains express or co-express ST [5,8].
Many alternative vaccine candidates designed specifically to
protect people against ETEC diarrhea are under clinical develop-
ment. Potential vaccines can be divided into two groups: inacti-
vated vaccines containing killed whole cells, purified CF antigens,
or inactivated LT; and live attenuated vaccines containing geneti-
cally modified, nonpathogenic strains of ETEC or alternative carrier
bacteria expressing the important ETEC antigens [9,10]. Most vac-
cine formulations have been based on LT or CFs from ETEC since
it has been reported that both antitoxin and antibacterial antibod-
ies are important to confer protection [11,12]. Vaccine candidates
including ETEC adhesins have also demonstrated be protective [13].
Anti-LT antibodies are important to protect against ETEC diar-
rheal disease as has been evidenced in ETEC challenge studies in
human adults and in infants naturally receiving breast milk con-
taining anti-LT IgA. These results suggested that antibodies can
provide immunity against toxigenic effect of LT and possibly avoid
ETEC colonization [14,15]. In the same way the drop of diarrheal
illness after five years of age in endemic regions correlates with
anti-LT antibody responses [16–18].
Heat-labile enterotoxin has been studied as a potential vaccine
antigen (Ag) and adjuvant [19,20] but its toxicity limits its use in
humans. Less toxic derivate forms have been developed, the most
relevant is attenuated double mutant heat-labile toxin LTR192G/
L211A (dmLT) that has a reduced toxigenic effect that allows its
use in humans [20–22]. dmLT has both antigenic and adjuvant
properties and it has been proved to be safe in oral and sublingual
studies, currently is being tested for intradermal delivery [23–26].
The most advanced oral ETEC vaccine candidate (ETVAX) is a
tetravalent, inactivated whole-cell ETEC vaccine containing dmLT,
currently under phase 2 clinical trial [27]. Recently it has been pub-
lished that dmLT can enhance the protective efficacy of an orally
delivered live attenuated vaccine expressing CS/CFA antigens in
humans [28].
At present, there are no clinical studies using oral subunit vac-
cine formulations against ETEC with dmLT as antigen. ETEC oral
vaccines containing dmLT as adjuvant are whole cell vaccines
[29,30] and dmLT as adjuvant in subunit vaccines has been
assessed only for parenteral vaccines. Previous studies reported
that a single oral dmLT dose of up to 100 mg is well tolerated in
human subjects. Although immune responses were better after a
single dose of 50 mg in humans [31]. Development of effective vac-
cines administered by oral route are restricted by the highly acidic
and degradative gastrointestinal ambient where Ags are denatured
or degraded. However, this route should not be dismissed since
effective mucosal immunogenicity can be achieved by an appropri-
ate Ag formulation that can prevent vaccine degradation at the gut.
In our previous work we demonstrated that a bacterial protease
inhibitor from Brucella abortus (U-Omp19) can be used as an
adjuvant in oral vaccine formulations [32]. Co-administration of
U-Omp19 with an Ag can (i) bypass the harsh environment of
the gastrointestinal tract partially inhibiting stomach and gut pro-
teases and consequently it increases the half-life of co-delivered
Ags while (ii) induces the recruitment, activation and increase Ag
half-life inside Ag presenting cells (APCs) [33]. Besides, it increases
the amount of Ag bearing dendritic cells at inductive sitesincreasing Ag immunogenicity [34]. Likewise U-Omp19 improves
protection against Toxoplasma gondii and Salmonella Typhimurium
challenge when is co-administered with subunit Ags in different
murine models [32,33,35,36]. Of note we have shown by circular
dichroism that U-Omp19 is pH- and temperature-resistant [33].
Recently we demonstrated that U-Omp19 inhibits protease activity
from murine intestinal brush-border membranes and cysteine
proteases from human intestinal epithelial cells (IECs) promoting
co-administered Ag accumulation within lysosomal compartments
of IECs. In addition, we have shown that co-administration of
U-Omp19 facilitated the transcellular passage of Ag through
epithelial cell monolayers in vitro and in vivo while did not affect
epithelial cell barrier permeability. Finally, oral co-delivery of
U-Omp19 in mice induced the increment of CD103+ CD11b
CD8a+ dendritic cells subset at Peyer’s patches. Ag oral administra-
tion with U-Omp19 increases the frequency of mucosal DCs
bearing the co-delivered Ag [37].
In this work we will evaluate the capacity of U-Omp19 to
increase immune responses against LT from ETEC and its ability
to improve protection against LT challenge when is combined with
dmLT in an oral vaccine formulation. We will also evaluate if
U-Omp19 can allow dmLT dose sparing by the oral route.2. Material and methods
2.1. Ethics statement
All experimental protocols were conducted in agreement with
international ethical standards for animal experimentation (Hel-
sinki Declaration and its amendments, Amsterdam Protocol of wel-
fare, and animal protection and National Institutes of Health, USA,
guidelines: Guide for the Care and Use of Laboratory Animals). The
protocols used were approved by the Institutional Committee for
the Care and Use of Experimentation Animals (CICUAE) from the
University of San Martin (UNSAM) (Permit Number: 04-2016),
Buenos Aires, Argentina.
2.2. Animals
Eight to twelve-week-old female BALB/c mice were obtained
from the Animal Facility of Instituto de Investigaciones Biotec-
nológicas (IIB-UNSAM). CD-1 mice were purchased from Charles
River (USA). Mice were housed in appropriate conventional animal
care facilities and handled according to international guidelines
required for animal experiments at IIB-UNSAM.
2.3. Immunogen and adjuvants
Attenuated double mutant heat-labile toxin LTR192G/L211A
(dmLT)was provided by PATH (Seattle, US) and used as immunogen
[31]. Recombinant U-Omp19 was expressed and purified as previ-
ously described [32]. LPS contamination from U-Omp19 was
adsorbedwith Sepharose-Polymyxin B (Sigma). Endotoxin determi-
nationwasperformedwith Limulus amoebocyte chromogenic assay
(LONZA). All U-Omp19 preparations used contained < 0.1 endotoxin
units per mg of protein. Heat-labile enterotoxin (LT) was provided
by John Clements (Tulane University, New Orleans, US).
2.4. Immunizations
Inbred female BALB/c and outbred CD-1 mice (n = 5–6/group)
were orally (intragastric) immunized with: (i) saline, (ii) dmLT
alone or (iii) dmLT with U-Omp19 (150 mg). Three doses of dmLT
were studied alone or plus U-Omp19: a dose of 25 mg used in clin-
ical trials [22] or 12.5 mg and 2.5 mg of dmLT.
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c mice were immunized following two protocols: (i) single dose or
(ii) two doses (at days 0 and 28).
All mice were fasted 2 h before and 2 h after immunization.
2.5. Determination of antibody levels at feces and sera
Feces and sera were obtained weekly as described previously
[32] to study LT- specific antibody responses (IgA and IgG in feces
and IgG, IgG1, IgG2a and IgA in sera) by indirect ELISA. Hence, 96-
well plates were coated with 0.1 mg/well of LT in carbonate buffer
(15 mM Na2CO3, 35 mM NaHCO3, 0.2 g/liter NaN3, pH 8.6) over-
night at 4 C. Plates were washed with PBS-Tween 0.05% and
blocked with 1% bovine serum albumin (BSA) for 1 h at 37 C.
Plates were then incubated with fecal extracts or sera (diluted in
PBS containing 1% BSA). Incubations at 37 C for 2 h for fecal sam-
ples and 1 h for sera samples were performed and then plates were
washed and incubated with HRP conjugated anti-mouse IgA, IgG
(SIGMA, St. Louis, MO, USA), IgG1 or IgG2a (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) for 1 h at 37 C. Then, TMB
(3,3́,5,5́tetramethylbenzidine) was added and reaction was
stopped with H2SO4 4 N and immediately read at 450 nm to collect
end point ELISA data.
End-point cut-off values for serum titer determination were cal-
culated as the mean specific optical density (OD) plus 3 standard
deviation (SD) from sera of saline immunized mice and titers were
established as the reciprocal of the last dilution yielding an OD
higher than the cut-off. ELISA assay was performed the same day
of feces collection.
Anti-U-Omp19 ELISA was performed as previously described
[38].
2.6. Determination of antibody avidity
Anti-LT IgG avidity was measured in sera of immunized animals
after last vaccination as previously described [39]. Briefly, 96-well
plates were coated, washed, and blocked as described above. Then,
sera samples were plated in duplicates for 1 h and plates were
washed and incubated with either 6 M urea solution or PBS for
10 min at 37 C. After washing, plates were incubated with anti-
mouse IgG-HRP (SIGMA, St. Louis, MO, USA) and then washed
and revealed with TMB. Reaction was stopped with H2SO4 4 N
and immediately read at 450 nm to collect end point ELISA data
and calculate avidity indexes as the ratio of the O.D. in the urea-
treated wells to untreated wells.
2.7. Patent mouse gut assay
After last immunization mice were challenged with LT follow-
ing the patent (nonoccluded gut) mouse assay as previously
described [40]. Briefly, the animals were fasted overnight and chal-
lenged orally with LT at doses of 75 mg to CD-1 mice and 50 mg to
BALB/c mice in 0.5 ml saline solution. After 3 h of inoculation the
animals were sacrificed, the entire intestine from duodenum to
anus from each mouse was removed carefully to retain any accu-
mulated fluid and residual mesentery was eliminated prior to
weigh them. The carcass was weighed separately, and individual
gut/carcass (G/C) ratio was calculated as indicator of intestinal
fluid accumulation. The best dose of LT to challenge mice was cho-
sen based on previous experiments administering different
amounts of native LT to CD-1 or BALB/c unimmunized animals.
2.8. Neutralization of toxin-mediated intestinal fluid secretion
The neutralization capacity of sera was tested in vivo as previ-
ously described [23]. BALB/c mice were challenged intragastricallywith 0.5 ml saline solution containing 50 lg of LT pre-incubated
with dilutions of sera for 30 min at room temperature. After 3 h
animals were sacrificed, the entire intestine from duodenum to
rectum was carefully removed to retain any accumulated fluid,
and the residual mesentery was removed prior to weigh. Entire
intestine and large and small intestine were weighed. The carcass
was weighed separately. LT-induced diarrhea is shown as gut/car-
cass ratio.2.9. Data analysis
Statistical analysis and plotting were performed using Graph-
Pad Prism 7 software (GraphPad, San Diego, CA). In the case of data
from antibody levels (IgA, IgG, IgG1 and IgG2a), avidity in sera and
feces samples and patent gut mouse assay data (with logarithmic
transformation when necessary) were tested for normality and
homoscedasticity before using parametric statistics (one-way
ANOVA with Bonferroni post-test, two-way ANOVA or Unpaired
T test). Normality was tested using the D’Agostino-Pearson nor-
mality test, and homogeneity of variances was tested using the
Levene Median test. In cases where non-normality was suspected
(data from in vivo LT neutralization experiments) statistical analy-
sis was performed using non-parametric test (Unpaired Mann-
Whitney T test). Results shown are representative of at least two
independent experiments. The number of replicates per experi-
mental group is five or six. Results were expressed as
mean ± SEM. Significance level was set at p < 0.05.3. Results
Oral co-delivery of U-Omp19 with dmLT increases anti-LT
mucosal antibody responses and improves protection against
heat-labile enterotoxin oral challenge in CD-1 mice.
Our first aim was to evaluate the effect of U-Omp19 co-delivery
on dmLT immunogenicity in outbred mice. Though outbred ani-
mals may cause more variability in the experiments, they are more
akin to the human population in terms of genetic diversity. We
selected the outbred genetically heterogeneous CD-1 strain of mice
because it has been used previously to investigate the protective
capacity of different vaccine formulations against Escherichia coli
intestinal colonization [13,41]. Thus, CD-1 mice were orally (i.g)
immunized at days 0, 28 and 42 with i) saline, ii) dmLT alone or
iii) dmLT + U-Omp19. To investigate if U-Omp19 could have a dose
sparing effect, three doses of dmLT (25, 12.5 and 2.5 mg) were eval-
uated alone or plus U-Omp19.
Levels of anti-LT antibodies in feces and sera were evaluated by
ELISA. Two weeks after second and third immunization, U-Omp19
co-delivery induced a significant increment in mucosal anti-LT IgA
antibodies with 12.5 mg dose of dmLT in comparison with dmLT
delivered alone. There was a slightly but not statistically significant
increase in anti-LT IgG antibodies at feces in the group immunized
with 25 and 12.5 mg of dmLT plus U-Omp19 in comparison with
dmLT alone Fig. 1A. Time progression analysis of anti-LT IgA levels
at feces from animals that were immunized with 12.5 mg of dmLT
indicated that the antibody (Ab) response was low after first and
second immunization and peaked after third immunization
(Fig. 1A). This response remained higher, but not statistically dif-
ferent to dmLT alone at three weeks after last immunization (Sup-
plementary Fig. 1). In serum, there were no differences in the
magnitude of anti-LT IgG or IgA titers between the groups with
or without U-Omp19 at any of the doses of dmLT evaluated
(Fig. 1B). Nevertheless, isotypes profile in sera changed after
co-administration of U-Omp19 with dmLT where levels of IgG2a
were significantly increased in comparison with the group that
received the same dose of dmLT (25 mg) alone (Fig. 1C). Of note,
Fig. 1. Oral co-administration of U-Omp19 with dmLT increases anti-LT Ab responses and protects against LT challenge in outbread mice. CD-1 mice were orally immunized
at days 0, 28 and 42 with: (i) saline, (ii) dmLT (25, 12.5 and 2.5 mg/mouse) or (iii) dmLT + U-Omp19. Systemic and mucosal antibodies were evaluated by ELISA. A. anti-LT IgA
and IgG levels in feces was evaluated two weeks after last immunization (left). Time course of anti-LT fecal IgA in the groups of mice immunized with dmLT (12.5 mg) alone or
plus U-Omp19 (right). Results are shown as optical density (OD) 450 nm. **P < 0.01. OneWay ANOVA with Bonferroni post-test. B. Titers of anti-LT IgG and IgA in serum three
weeks after last immunization. C. IgG isotypes in serum of immunized animals. Anti-LT IgG1 and IgG2a titers were determined by ELISA three weeks after last immunization.
**P < 0.01, ***P < 0.001. One Way ANOVA with Bonferroni post-test. D. Patent mouse gut assay. Immunized mice were orally challenged 1 month after last immunization with
LT (75 lg/mice) and 3 h later the entire intestine from duodenum to anus was excised. Total intestine, large and small intestine sections and carcasses were separately
weighed and individual gut/carcass weight ratios for each mouse calculated. *P < 0.05, **P < 0.01. Unpaired T test. Data points represent individual mice. Data from one
representative experiment of two independent experiments.
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nized group (Supplementary Fig. 2A).
Antibody responses are important to prevent ETEC bacterial
adherence and toxins neutralization to avoid ETEC-associated diar-
rhea. Ability of vaccine formulation to prevent LT-induced diarrhea
was evaluated by the patent mouse gut assay one month after last
immunization. To do this, immunized CD-1 mice were challenged
orally with LT (75 lg) and 3 h later mice were sacrificed, and each
intestine and carcass was weighted. A significant protection was
achieved in mice immunized with 25 lg dmLT plus U-Omp19
while dmLT alone did not protect against LT oral challenge
(Fig. 1D). Protection was also observed with the dose of 2.5 lg
dmLT plus U-Omp19 considering large intestine weight. These
results indicate that U-Omp19 can increase dmLT immunogenicity
and the efficacy to neutralize LT in vivo following an immunization
protocol consisting of one primary immunization and two boosts
in outbred CD-1 mice.3.1. U-Omp19 in the oral vaccine formulation can help to reduce dmLT
dose in BALB/c mice and improves protection against heat-labile
enterotoxin oral challenge
To investigate if U-Omp19 improves dmLT immunogenicity in
different genetic backgrounds despite their intrinsic variability
we also tested BALB/c mice. We evaluated if U-Omp19 can help
to reduce the number of doses administered, thus BALB/c mice
were immunized two times with a first immunization at day 0
and a boost at day 28. Again, three doses of dmLT were evaluated
(25 mg, 12.5 mg or 2.5 mg) with or without U-Omp19 in the oral for-
mulation. Two weeks after second immunization there was an
increment of anti-LT IgA and IgG in feces in the group of mice that
received 12.5 mg of dmLT co-delivered with U-Omp19 (Fig. 2A), in
comparison with dmLT immunization alone. Anti-LT IgA antibodies
remained higher in the group immunized with dmLT 12.5 plus U-
Omp19 up to three weeks after last immunization although the
Fig. 2. Oral co-administration of U-Omp19 with dmLT induces LT specific immune responses and protects against LT challenge in BALB/c mice. BALB/c mice were orally
immunized at day 0 and 28 with (i) saline, (ii) dmLT (25, 12.5 or 2.5 mg/mouse) or iii) dmLT + U-Omp19. A. Anti-LT IgA and IgG levels were evaluated in feces by ELISA two
weeks after second immunization (left). Time course progression of anti-LT IgA in feces in the groups immunized with dmLT (12.5 mg) alone or plus U-Omp19. Results are
shown as optical density (OD) 450 nm. *P < 0.05, **P < 0.01. One Way ANOVA with Bonferroni post-test. B. Titers of specific anti-LT antibodies in serum two weeks after last
immunization (left) and time course progression of serum anti-LT IgG in dmLT (12.5 mg) alone or plus U-Omp19 immunized groups (right). C. IgG isotypes in serum of
immunized animals. Titers of IgG1 and IgG2a were determined by ELISA three weeks after last immunization. **P < 0.01, ***P < 0.001. One Way ANOVA with Bonferroni post-
test. D. Patent mouse gut assay. Immunized mice were orally challenged with LT (50 lg/mice) and 3 h later the entire intestine from duodenum to anus was excised. Total
intestine, large and small intestine sections and carcasses were separately weighed and individual gut/carcass weight ratios for each mouse calculated. *P < 0.05. Unpaired T
test. Data points represent individual mice. Data from one representative experiment of two independent experiments.
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Fig. 3). Also, serum antibodies had shown a significant increment in
anti-toxin IgG and IgA in the group that was immunized with
12.5 mg of dmLT plus U-Omp19 (Fig. 2B). After examining the pro-
gression of IgG titers at different time points, we observed that the
increment in anti-LT IgG titers was maintained up to four weeks
after the second immunization in dmLT 12.5 plus U-Omp19 group
compared with the group administered with the same dose of
dmLT alone (Fig. 2B). After evaluating IgG isotypes, we observed
that IgG2a Abs predominate over IgG1 responses in the group of
12.5 of dmLT + U-Omp19. There were no differences in anti-LT
Abs at feces nor at sera when using 25 or 2.5 mg of dmLT with or
without U-Omp19 (Fig. 2C). Anti-U-Omp19 antibodies were not
detected in sera of any immunized group (Supplementary Fig. 2B).
One month after last immunization mice were challenged orally
with LT (50 lg) and patent mouse gut assay was performed. The
highest dose of dmLT (25 lg) co-delivered with U-Omp19 induceda significant reduction in fluid secretion after LT challenge either
after evaluating the whole intestine or large intestine weight
(Fig. 2D). U-Omp19 co-delivery with the mid-dose of dmLT
(12.5 lg) was also capable to reduce LT effect on the large intestine
fluid secretion in immunized mice (Fig. 2D).
Thus, results obtained after the prime-boost protocol revealed
that vaccine formulation containing U-Omp19 can help to induce
systemic and mucosal Ag specific antibody responses in mice using
a lower dose of dmLT (12.5 lg) while inducing protection after LT
challenge.
Finally, dose sparing strategy was evaluated after one immu-
nization with the Ag dmLT. A single oral immunization protocol
was performed in BALB/c mice testing again three doses of dmLT
(25, 12.5 or 2.5 lg) alone or in presence of U-Omp19. Results
showed that mucosal specific IgA and IgG antibodies were
increased two weeks after single immunization when the highest
dose of dmLT (25 lg) plus U-Omp19 was used, in comparison with
5032 L.M. Coria et al. / Vaccine 38 (2020) 5027–5035dmLT delivered alone (Fig. 3A). This improvement was not
observed when using the lower doses of dmLT (12.5 or 2.5 mg).
Likewise, anti-LT IgG and IgA antibodies in serum were increased
after oral immunization with the highest dose of dmLT plus U-
Omp19 in comparison with dmLT delivered alone (Fig. 3B). Levels
of systemic IgG isotypes were changed after co-administration of
25 lg dmLT with U-Omp19 in comparison with dmLT alone, in this
case IgG1 titers were significantly increased three weeks after oral
immunization (Supplementary Fig. 4). It is important to state that
anti-U-Omp19 antibodies were not detected in sera of any immu-
nized group (Supplementary Fig. 2C).
Since the ability of ETEC vaccines to induce mucosal antibodies
with high avidity may also influence their protective efficacy we
measured antibody avidity of IgG and IgA in serum from mice of
all groups. There was a significant increase in anti-LT IgG and IgA
avidity after a single oral administration of 25 or 12.5 mg of dmLTFig. 3. Single dose oral co-administration of U-Omp19 with dmLT increases anti-LT Ab
orally immunized with (i) saline, (ii) dmLT (25, 12.5 or 2.5 mg) or (iii) dmLT + U-Omp19
immunization (left). Time course progression of anti-LT IgA levels of the groups immuniz
density (OD) 450 nm. **P < 0.01, ***P < 0.001. One Way ANOVA with Bonferroni po
immunization (left) and time course progression of anti-LT IgG of the groups immunize
ANOVA with Bonferroni post-test. C. Avidity of anti-LT IgG and IgA was evaluated in the s
as Avidity Index (optical density (OD) after incubation with UREA/O.D. after incubatio
neutralization assay. LT was incubated with pooled sera from immunized mice during 1
were killed and the entire intestine from duodenum to anus was excised. Whole intest
individual gut/carcass weight ratios for each mouse was calculated. *P < 0.05. Mann-W
experiment of two independent experiments.plus U-Omp19 in comparison with dmLT delivered alone (same
dose) (Fig. 3C). Immunization protocols with one or two boosts
did not modify antibody avidity in serum (data not shown).
Finally, in vivo neutralization of toxin mediated diarrhea was
assessed by preincubating LT with a pool of sera from each group
of vaccinated animals. Then, preincubated LT was used to chal-
lenge non-immunized animals and patent mouse gut assay was
performed. Interestingly, sera from dmLT (25 mg) plus U-Omp19
vaccinated mice significantly inhibited LT effect on intestine
inflammation compared with sera from the group immunized with
dmLT alone (Fig. 3D).
These results together indicate that oral co-administration of
U-Omp19 with dmLT can increase LT-specific mucosal and sys-
temic antibody responses and improve avidity and neutralization
capability of antibodies after a single dose immunization schedule
in BALB/c mice. In summary, results demonstrated that U-Omp19responses that neutralizes LT induced diarrhea in BALB/c mice. BALB/c mice were
at day 0. A. Anti-LT IgA and IgG were evaluated in feces by ELISA three weeks after
ed with dmLT (25 mg) alone and plus U-Omp19 (right). Results are shown as optical
st-test. B. Titers of specific anti-LT antibodies in serum three weeks after single
d with dmLT (25 mg) alone or plus U-Omp19 (right). *P < 0.05, **P < 0.01. One Way
erum of immunized animals three weeks after last immunization. Results are shown
n in PBS). *P < 0.05, **P < 0.01. One Way ANOVA with Bonferroni post-test. D. LT
h and then it was administered orally to mice. Three hours after challenge, animals
ine, large and small intestine sections and carcasses were separately weighed and
hitney T test. Data points represent individual mice. Data from one representative
L.M. Coria et al. / Vaccine 38 (2020) 5027–5035 5033administration would be useful for antigen sparing strategies in
oral vaccine formulations against ETEC.4. Discussion
Usefulness of U-Omp19 as an oral vaccine adjuvant in mice has
been previously reported. We have shown that protease inhibitor
properties of U-Omp19 allow it to bypass the harsh environment
of the gastrointestinal tract limiting co-administered Ag digestion
and consequently increasing Ag amount at immune inductive sites.
In addition, immunostimulatory properties of U-Omp19 induce
mucosal and systemic Ag-specific immune responses (Th1, Th17
and CD8+ T cells) after oral co-administration with the Ag
[33,36,37].
In this work, we evaluated the immunogenicity and protective
efficacy of an oral formulation containing U-Omp19 and dmLT as
antigen in mice. LT is one of the principal ETEC virulence factors
and it has been studied as a potential vaccine antigen, as well as
an adjuvant to induce mucosal immune responses [20]. The non-
toxic LT double mutant (LTR192G/L211A or dmLT) has been shown
to be immunogenic in animals and human trials and protective in
animal models [28,42]. Also, dmLT has demonstrated adjuvanticity
inmice. Thus, this protein has the potential to be both a stand-alone
vaccine as well as a mucosal adjuvant for other co-administered
vaccine antigens [31]. Nevertheless, recent human clinical trials
has demonstrated moderate immunogenicity at doses up to 50 mg
of dmLT administered by oral or sublingual route [42]. Mucosal
delivery of vaccines is more effective for eliciting mucosal immune
responses, however, oral vaccination against enteric pathogens is
difficult to achieve because of the gastric environment and the
potential for inducing tolerance to the vaccine Ag . Our results
demonstrated that co-administration of dmLT with U-Omp19 by
oral route increased dmLT immunogenicity inducing specificmuco-
sal and systemic antibodies leading to protection against LT entero-
toxin challenge inmice. Indeed, it has been previously reported that
protease inhibitor properties of U-Omp19 can increase the amount
of CTB that reach mucosal surfaces after its oral delivery in mice
enhancing its immunogenicity [37].
Different routes of administration studies have demonstrated
clear differences in the doses of dmLT required to induce immune
responses, standard dose of dmLT as adjuvant by oral route is 10 to
25 mg while for sublingual route is 1 to 5 mg [42]. Indeed, high doses
of Ag can suppress the magnitude of responses and also bias to an
antibody/Th2 response as it was seen in the clinical studies for
ETVAX vaccine where 10 mg dmLT was superior to 25 mg [22]. In
this work, we studied three different doses of dmLT and three dif-
ferent protocols of immunization. Higher antibody responses were
observed after immunization with higher doses of dmLT (12.5 and
25 mg) in all immunization schedules. Following immunization
protocols with one primary immunization and one or two boosts
U-Omp19 increases anti-LT specific mucosal antibodies in the dose
of 12.5 mg of dmLT while after a single oral dose only the highest
dose of dmLT (25 mg) plus U-Omp19 could increase the levels of
anti-LT antibodies in comparison with dmLT alone. Of note,
U-Omp19 improved the induction of systemic anti-LT antibodies
in the immunization protocols with fewer number of doses com-
pared with the three-doses immunization protocol where there
were no differences in the titers of Ag-specific IgG or IgA antibodies
in presence or absence of U-Omp19. Thus, U-Omp19 seems to be
crucial to increase mucosal antibodies when the Ag is given in
low or suboptimal dose. In conclusion, addition of U-Omp19 to
the vaccine formulation can improve anti-LT antibody responses
with reduced number of administrations or Ag dose.
On the other hand, results of enterotoxin neutralization capac-
ity of induced antibodies showed that animals immunized with thehighest dose of dmLT plus U-Omp19 were capable to reduce
intestinal fluid secretion after LT oral challenge in all the immu-
nization schedules. The anti-toxin antibody responses observed
were not totally consistent or correlated with the protective effi-
cacy against LT challenge since the best dose of dmLT that induced
significant mucosal antibody responses was not the same that pre-
vented LT enterotoxicity after three doses of immunization.
Although neutralizing antitoxin antibodies have been associated
with ETEC protection [43] physiology of antibody immune
responses could explain the discrepancy observed in our results.
First, oral challenge with LT enterotoxin could trigger a local
inflammatory response that stimulate antibody secreting B cells
present in the inductive sites of the intestinal mucosa. In fact,
the group of animals that was protected after LT oral challenge
showed higher, but not significant, antitoxin mucosal antibodies
after co-administration of U-Omp19 with 25 mg of dmLT
(Fig. 1A). Moreover, the transport of systemic antibodies at the
lumen of gastrointestinal tract via enterohepatic circulation should
be taken in account (J. Clements, personal communication) [44]. In
fact, the levels of Ab measured in the samples of feces or serum not
always correlates with the amount of antibodies that can induce
protection in vivo.
The capacity of an adjuvant to switch IgG isotypes is of signifi-
cance for the outcome of humoral and cellular responses against
the Ag. IgG2 isotype has the highest affinity for the Fcc receptors
that mediate antibody-dependent cellular cytotoxicity and phago-
cytosis (ADCC and ADCP) [45]. Therefore, adjuvants such as the
TLR4 agonist SLA-SE that promote IgG2a class-switching in mice
may be beneficial to block either adherence via colonization factors
or cAMP flux caused by LT and/or ST [46]. U-Omp19 promoted the
production of anti-LT IgG2a antibodies over IgG1 in serum of
immunized animals after two or three immunizations (Figs. 1C
and 2C). On the contrary, after a single oral dose dmLT plus U-
Omp19 induced higher levels of IgG1 antitoxin antibodies. It has
been proposed that the ability of ETEC vaccines to induce antibod-
ies with high avidity may also influence their protective efficacy
[13,18]. Of note, the inclusion of U-Omp19 in dmLT vaccine formu-
lation also increased the avidity against LT of IgG elicited Ab in
comparison with the administration of dmLT alone (Suppl. Fig. 4
and Fig. 3C). Indeed, antibody avidity has been shown to correlate
with the presence of Ag-specific memory B cells following enteric
pathogen infection [39].
Vaccine manufacturing process is time-consuming and many
times the production capacity is limited [7]. Therefore, it is impor-
tant to improve vaccine manufacturing strategies and reduce its
cost by developing new techniques or reducing antigen dose.
Incorporation of Ag-sparing adjuvant(s) into vaccine formulations
cans solve this problem and could be critical in the case of pan-
demic outbreaks [47,48]. Admixing U-Omp19 adjuvant with a vac-
cine could be an effective and efficient approach for antigen
sparing, and consequently improvement of vaccine production
capacity. On the other hand, inclusion of the LT toxoid component
in the vaccine may help broaden protection to potentially other
enteric pathogens like Salmonella or Campylobacter [25,49].
Therefore anti-LT based vaccine can be protective against a broader
array of ETEC pathotypes [50]. Interestingly, several studies now
indicate that dmLT can also provide nonspecific protection from
disease and that may be due to activation of innate immunity
[20,25]. Thus, it will be interesting to study in future works if
U-Omp19 modulate or increase innate immunity induced by dmLT.
Overall, an oral vaccine formulation containing dmLT and
U-Omp19 can induce antitoxin antibody responses and can be
effective against ETEC induced diarrhea. This work served as proof
of concept on the inclusion of dmLT together with U-Omp19 in a
vaccine formulation against ETEC. Thus, our next steps are combin-
5034 L.M. Coria et al. / Vaccine 38 (2020) 5027–5035ing dmLT, U-Omp19 and new ETEC Ags in oral vaccine
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